AcquisitionOther
TriSalus Life Sciences, Inc. acquired target
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
TriSalus Life Sciences, Inc. -> target · $0.0001
The Company's platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy.
Open source record (SEC) ↗